Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells

Despite recent therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease with limited therapeutic options. Immune checkpoint inhibitors (ICIs) have demonstrated promising results in many cancers, but thus far have yielded little clinical benefit in PDAC. Based on re...

Descripción completa

Detalles Bibliográficos
Autores principales: Harper, Megan M., Lin, Miranda, Cavnar, Michael J., Pandalai, Prakash K., Patel, Reema A., Gao, Mei, Kim, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262213/
https://www.ncbi.nlm.nih.gov/pubmed/35797269
http://dx.doi.org/10.1371/journal.pone.0270832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262213/
https://www.ncbi.nlm.nih.gov/pubmed/35797269
http://dx.doi.org/10.1371/journal.pone.0270832

Ejemplares similares